Important Deadline for PepGen Inc. Investors Facing Securities Fraud Claims

Investors Alert: Take Action on PepGen Inc. Securities Fraud

PepGen Inc. (NASDAQ: PEPG) has recently found itself at the center of a significant legal development that could have major implications for its investors. As reported, Rosen Law Firm, a renowned global investor rights law firm, is urging purchasers of PepGen’s securities between March 7, 2024, and March 3, 2025, to take swift action before the impending lead plaintiff deadline on August 8, 2025.

Understanding the Class Period

This class period encompasses a timeframe during which many investors may have acquired PepGen stock, potentially leading to significant financial losses due to misleading information disseminated by the company. Rosen Law Firm highlights that investors may be entitled to compensation without upfront costs, based on a contingency fee arrangement that many law firms offer.

What You Need to Know

If you purchased PepGen securities during the stated period, now is the moment to assess your situation. Joining the class action lawsuit does not require immediate costs, allowing you to pursue your rights without financial barriers. Interested parties can join the lawsuit by visiting this link or contacting attorney Phillip Kim directly for further assistance.

Role of the Lead Plaintiff

In securities class action lawsuits, the lead plaintiff acts on behalf of the rest of the investors in guiding the litigation. Individuals wishing to assume this role must file their motions by the deadline. This representation is critical as it drives the direction and strategy of the lawsuit, which could prove beneficial in not only seeking damages but also in restoring investor confidence.

Rosen Law Firm's Credentials

It’s crucial to choose legal representation wisely. Rosen Law Firm is recognized for its track record in securities class actions, having secured substantial settlements, including the largest settlement against a Chinese company at the time. The firm has consistently ranked highly in multiple years for its success in this realm, achieving settlements worth hundreds of millions of dollars. In 2019 alone, they recovered over $438 million for investors and have held a commendable reputation in the legal community.

Details of the Case Against PepGen

The pending lawsuit asserts that throughout the class period, PepGen provided false and misleading statements regarding clinical trials and the efficacy of its treatment, PGN-EDO51. Investors were allegedly misled to believe that the treatment was both effective and safe, in stark contrast to findings that indicated potential issues with the CONNECT2 study. Moreover, it suggests that the company was likely to halt the CONNECT2 study because it was dangerous or otherwise deficient for FDA approval. These misrepresentations resulted in inflated stock prices, which collapsed when the true facts came to light.

Expected Outcomes

As the lawsuit unfolds, investors affected by these misrepresentations may have a chance to recover losses through settlements or court rulings. However, it is essential to act quickly, as class certification is still pending, and investors potentially do not have counsel until they take the necessary actions to join the class or secure their representation individually.

To participate in this class action or to inquire about your rights as an investor, follow the instructions outlined on Rosen Law Firm’s website or reach out directly to their legal representations.

Conclusion

With a critical deadline approaching, investors should not procrastinate in exploring their legal options against PepGen Inc. As the firm navigates this complicated landscape of securities fraud, staying informed and proactive could prove pivotal in securing rightful compensation. Stay engaged with updates by following Rosen Law Firm on their social media platforms for the latest developments regarding this case.